ClinicalTrials.gg
Active, not recruitingNCT00580385Updated May 1, 2026

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

An interventional study of Tissue Procurement in Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
763
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Osteosarcoma · Memorial Sloan Kettering Cancer Center.

Enrollment
Largest of 10
763 · median 43
Started
1997
with 2 others
No phase
Only one
of the 21
Registered
15th of 21
by date

Among the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 3 that started in 1997, is the only one with no phase, and was the 15th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

2 of the 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Osteosarcoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.

Read the detailed description

When tumor tissue known or presumed to be a primary or secondary bone cancer or solid tumor with known elevated intra-tumoral pressure such as retinoblastoma is being removed or has been removed for diagnostic or therapeutic reasons a small sample of it will be obtained for this study. The tumor samples will be used to study in vitro, determinants of chemotherapy resistance and oncogenesis. These determinants will be correlated with histologic response to preoperative chemotherapy and clinical outcome (event free survival). In addition, blood samples (20ml) may be obtained before or after the procedure.

03

Conditions studied

  • Osteosarcoma

Browse trials for

Keywords

  • BONE
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with a presumed or known diagnosis of a primary or secondary bone cancer or other solid tumor who are having or have had a or surgery to remove tumor for diagnostic or therapeutic reasons. No tumors will be obtained solely for research purposes.
  • All adult patients (> or = to 18 yrs.) will have given written .
  • All minor patients (\<18 yrs.) will have given assent to the best of their ability to understand, and their parent or guardian will have given written informed consent

Exclusion criteria

Exclusion Criteria:

  • N/A
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
763 participants (actual)

Study arms

  • Experimental
    1

    Other: Tissue Procurement

Interventions

  • OtherTissue Procurement

    MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting

06

What researchers measure

Primary outcomes

  1. To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.

    Time frame: 2 years

Secondary outcomes

  1. To attempt to grow these tumor cells in short term culture to test the sensitivity of these cells to chemotherapeutic agents and to correlate cytotoxicity with biochemical and molecular studies.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1997, a primary completion of Aug 2027 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 24, 2007
Start
Aug 1997
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00580385
Responsible party
Sponsor
First posted
Dec 24, 2007
Start date
Aug 1997
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
May 1, 2026

Study contacts

Carol Morris, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion